Bupropion SR as an Anti-Craving Anti-Obesity Agent

描述(申请人提供)：随着肥胖症患病率的增加，现有的药物治疗仍然有效，研究控制食物摄入量的机制的药理学修改势在必行。安非他酮是一种用于戒烟的抗抑郁和抗饥饿剂，已被观察到通过一种未知的机制产生减肥。这种化合物的临床疗效被认为是去甲肾上腺素和多巴胺能活性的结果。多巴胺在调节食物奖赏方面起着既定的作用。这项拟议的研究的目的是检验安非他酮会减少超重和肥胖受试者的食物奖励和渴望这一基本假设。为了检验这一假设，将使用喂养实验室范例、72小时饮食回忆和有效的渴望问卷。对这项研究结果的影响包括提供对现有厌氧化合物安非他酮潜在独特的行为作用机制的洞察。这项研究结果的长期影响包括这种药物作为肥胖和暴饮暴食障碍等疾病的治疗干预的潜在研究。

DESCRIPTION (provided by applicant): As the prevalence of obesity increases and available pharmacotherapies remain of modest benefit, investigating the pharmacological modification of mechanisms that control food intake is imperative. Bupropion, an antidepressant and anti-craving agent for smoking cessation, has been observed to produce weight loss through an uncharacterized mechanism. The clinical efficacy of this compound is thought to result from noradrenergic and dopaminergic activity. Dopamine has an established role in modulating food reward. The objective of the proposed study is to test the primary hypothesis that bupropion will reduce food reward and craving in overweight and obese human subjects. To examine this postulate, a feeding laboratory paradigm, 72 hour dietary recall, and validated craving questionnaires will be used. Implications for the results of this study include providing insight into a potentially unique behavioral mechanism of action of the existing anorexigenic compound bupropion. Longer term implications for the results of this study include the potential investigation of this agent as a therapeutic intervention for conditions such as obesity and binge eating disorder.